The preoperative pan-immune-inflammation value is a novel prognostic predictor for with stage I-III colorectal cancer patients undergoing surgery

Purpose The pan-immune-inflammation value (PIV) is useful for stratifying outcomes in patients with metastatic colorectal cancer. However, it is unclear whether preoperative PIV can predict the surgical outcomes of patients with stage I-III colorectal cancer who receive surgery. Methods The records of 758 patients with stage I-III colorectal cancer who received surgical treatment were retrospectively reviewed. The preoperative PIV was calculated as follows: (neutrophil count x platelet count x monocyte count)/lymphocyte count. The cut-off value was determined using a receiver operating characteristic curve for overall survival. Results The cut-off value of the preoperative PIV was 376. Five hundred sixty-eight patients (74.9%) had low values (<= 376), and 190 (25.1%) had high values (> 376). Univariate and multivariate analyses revealed that the PIV (> 376/ <= 376) (HR 2.485; 95% CI 1.552-3.981, P < 0.001) was significantly associated with overall survival, as well as age (> 60/ <= 60, years) (HR 1.988; 95% CI 1.038-3.807, P = 0.038), globulin-to-albumin ratio (> 0.83/ <= 0.83) (HR 2.013; 95% CI 1.231-3.290, P = 0.005) and postoperative complication (C-D grade III-V/0-II) (HR 1.991; 95% CI 1.154-3.438, P = 0.013). The Kaplan-Meier method and log-rank test showed significant differences in overall survival between patients with stage I-III disease with high (> 376) and low (<= 376) PIVs. Conclusion The preoperative PIV is useful for predicting surgical outcomes in patients with stage I-III colorectal cancer.

Automated summary

Preoperative pan-immune-inflammation value (PIV) can predict the surgical outcomes of patients with stage I-III colorectal cancer.